Inhibition of in vitro HBsAg production by amphotericin B and ketoconazole.
The effects of amphotericin B, ketoconazole, and adenine arabinoside on production of hepatitis B surface antigen (HBsAg) particles by the human hepatoma cell line PLC/PRF/5 were examined. In addition, the effects of these drugs on cellular protein synthesis were determined. These drugs caused a dose-dependent decrease in HBsAg production that was paralleled by a decrease in cellular protein synthesis. Ketoconazole was the most active of these drugs and the most specific, causing a 72% reduction in HBsAg production with only a 38% reduction in protein synthesis. These data suggest that further studies evaluating ketoconazole for the treatment of chronic hepatitis B virus infection in animals are warranted.
Pottage
J C
JC
Kessler
H A
HA
D000666:Amphotericin B / Q000494:pharmacology*; D000951:Antigens, Neoplasm / Q000096:biosynthesis; D000998:Antiviral Agents / Q000494:pharmacology / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000276:immunology*; D002460:Cell Line; D003864:Depression, Chemical; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical; D006509:Hepatitis B / Q000188:drug therapy; D006514:Hepatitis B Surface Antigens / Q000096:biosynthesis*; D006801:Humans; D007654:Ketoconazole / Q000494:pharmacology*; D008113:Liver Neoplasms / Q000276:immunology*; D009363:Neoplasm Proteins / Q000096:biosynthesis; D014740:Vidarabine / Q000494:pharmacology*
D000951:Antigens, Neoplasm; D000998:Antiviral Agents; D006514:Hepatitis B Surface Antigens; D009363:Neoplasm Proteins; D000666:Amphotericin B; D014740:Vidarabine; D007654:Ketoconazole